FDA denies Encysive's blood pressure drug again

09/6/2007 | Forbes

The drug regulator has again declined to approve hypertension treatment Thelin, claiming that the drug is not effective enough and that a new study is needed before the drug could be reconsidered for approval, biotech firm Encysive Pharmaceuticals said Thursday. Encysive maintains that it has addressed the FDA's queries in its previous letter to the company.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations